SHERIDAN, WYOMING - April 13, 2026 - The European Medicines Agency (EMA) has deployed its first social media campaign using partnered content creators, targeting the surge of misinformation surrounding GLP-1 receptor agonists. The #HealthNotHype initiative enlists healthcare professionals and nutrition experts from seven EU Member States to deliver evidence-based messaging on Instagram, where GLP-1 conversations have reached high volumes and often circulate without medical oversight. The campaign addresses a direct regulatory concern: soaring public interest in these medicines has generated parallel risks, including counterfeit product sales, unsupervised use, and misrepresentation of clinical outcomes. Running for approximately one month from launch, the initiative marks a strategic shift for EMA toward direct-to-public digital engagement.
Why GLP-1 medicines demand a public communication response
GLP-1 receptor agonists were originally developed for type-2 diabetes management, but several formulations have since received regulatory approval for weight management in patients with obesity and related health conditions. Their expanded indication, combined with celebrity endorsements and viral social media coverage, has pushed these medicines into mainstream public discourse well beyond their intended clinical population. EMA's concern is not limited to misuse among existing patients - the agency is responding to a broader pattern where non-indicated populations are seeking access through unregulated or illegal channels.
Counterfeit GLP-1 products have emerged as a concrete safety risk in European markets, compounding the challenge of misinformation. EMA Executive Director Emer Cooke stated that these medicines are not magic solutions for weight loss, carry both benefits and risks, and require long-term commitment alongside lifestyle changes under physician supervision. The agency's decision to enter the content creator space reflects a judgment that traditional regulatory communications channels are insufficient to intercept conversations already happening on social platforms at scale.
Campaign structure and creator selection criteria
EMA selected content creators from seven EU Member States to provide balanced geographical representation across the European Union. The selection criteria prioritized credibility in healthcare communication, alignment with evidence-based information principles, transparency, and independence from commercial interests. The majority of participating creators are practicing healthcare professionals or accredited nutrition experts - a deliberate choice to ensure the content carries professional authority rather than influencer opinion.
Instagram was designated as the primary campaign channel, chosen because of the concentration of GLP-1-related content and audience engagement already present on the platform. Throughout the campaign period, creators will publish audiovisual content on their individual channels and drive active follower participation through quizzes and polls - formats designed to test comprehension and surface misconceptions in real time rather than deliver passive broadcast messaging.
Regulatory and public health framing
The campaign operates explicitly within EMA's mandate to protect public health through validated scientific communication. By embedding regulatory messaging within creator-led content, EMA is attempting to reach audiences who may distrust or simply not encounter formal agency communications. The framing of GLP-1 medicines as long-term treatments requiring lifestyle integration and medical supervision directly counters the dominant social media narrative, which frequently positions them as standalone, rapid weight-loss solutions.
The initiative also carries an implicit signal to EU Member State health authorities: EMA is expanding its communication toolkit to address health misinformation at the source - on social platforms - rather than relying solely on prescriber education or post-market surveillance mechanisms. This approach aligns with broader EU digital health policy directions and positions EMA as an active participant in public-facing health discourse.
Business impact
Pharmaceutical compliance and regulatory affairs teams at companies marketing GLP-1 receptor agonists in the EU should treat this campaign as a leading indicator of EMA's intent to police the information environment around high-profile medicines. If the #HealthNotHype model proves effective, EMA is likely to expand it to other therapeutic categories with high social media visibility - requiring manufacturers to audit their own digital communications and third-party promotional activity for alignment with agency-approved claims.
Market access and brand management leads at GLP-1 manufacturers face a more immediate operational consideration: EMA's public messaging directly frames these medicines as requiring physician oversight and lifestyle modification, reinforcing the prescription-only model and creating a regulatory backdrop that complicates any direct-to-consumer positioning. Healthcare distribution and pharmacy procurement managers should also monitor downstream effects - increased patient awareness of safety requirements may influence demand patterns, prescription volumes, and the need for patient support program infrastructure across EU markets in 2026 budget cycles.